Consultation on Prescription Drug List-Naloxone

Health Canada is providing the public with an opportunity to provide comments and feedback regarding the proposal to remove naloxone from the Prescription Drug List (PDL). Loss of life due to opioid overdoses - both accidental and voluntary - constitutes a serious public health concern. The large increase in opioid overdose episodes has prompted the provinces to design programs to provide greater access to naloxone at the site of the overdose, either through first responders or “take-home programs”. These programs are hindered by the prescription status of naloxone. The provinces and territories have collectively asked Health Canada to re-evaluate the status of naloxone. For more information on the proposal or to provide comments/feedback, visit the Health Canada website by selecting the link below.

Notice: Prescription Drug List (PDL): Naloxone

Changes to Renewal Deadlines

Changes to the renewal deadlines will also be in effect for the 2016/2017 registration renewal year. Pharmacy permits holders, pharmacists and pharmacy technicians will be required to have their registration renewals completed and any required documentation submitted to the College office by March 15. Late registration penalties will be applied thereafter. Any member who does not submit their registration renewal by April 1 will be considered a new applicant and will be required to complete the initial application process for licensure.

Dal CPE Survey

Dal CPE is looking for input from pharmacists and pharmacy technicians on future pharmacy education opportunities through a 10 minute survey. To access the survey, please select the link below. When you complete the survey, you will be entered into a draw for a $75 gift card to a retailer of your choice.

Survey

Visit the Dal CPE website for more information on current programs being offered.

Dal CPE